Delavirdine and Kaletra

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using ritonavir together with delavirdine may increase the effects of ritonavir. Contact your doctor if you experience easy bruising or bleeding, signs of a new infection, such as fever or chills, cough, or flu symptoms, severe pain in your upper stomach spreading to your back, nausea and vomiting, fast heart rate, or loss of appetite, dark urine, clay-colored stools, and jaundice (yellowing of the skin or eyes). If your doctor does prescribe these medications together, you may need a dose adjustment or special test to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor

MONITOR: Coadministration with delavirdine may increase the plasma concentrations of ritonavir. The mechanism is delavirdine inhibition of ritonavir metabolism via CYP450 3A4. In 12 HIV-infected patients stabilized on antiretroviral therapy that included ritonavir 600 mg twice a day as the sole protease inhibitor, addition of delavirdine (400 mg three times a day for 21 days) increased the mean peak plasma concentration (Cmax), area under the concentration-time curve (AUC) and trough plasma concentration (Cmin) of ritonavir by 66%, 64% and 81%, respectively, compared to baseline. Ritonavir did not significantly affect the steady-state concentrations of delavirdine when compared to those from a reference database for delavirdine administered with food. The combination was well tolerated in the study, and no serious adverse event occurred. With respect to lower dosages of the combination, no significant interaction occurred when delavirdine 400 mg was administered with ritonavir 300 mg twice a day in healthy volunteers. However, it is uncertain whether these data are applicable to HIV-infected patients, as altered patterns of drug metabolism have been observed in this population.

MANAGEMENT: Appropriate dosages for the combination of ritonavir and delavirdine with respect to safety and efficacy have not been established. Patients given the combination should be advised to notify their physician if they experience potential signs of ritonavir intolerance such as severe nausea, vomiting, anorexia, abdominal pain, taste perversion, and circumoral and peripheral paresthesias. The effect of delavirdine on lower dosages of ritonavir (e.g., 100 or 200 mg twice a day as a pharmacokinetic booster of other protease inhibitors) in HIV-infected patients is unknown.

Delavirdine

Generic Name: delavirdine

Brand name: Rescriptor

Synonyms: n.a.

What is Delavirdine?

Kaletra

Generic Name: lopinavir / ritonavir

Brand name: Kaletra

Synonyms: n.a.

What is Kaletra?